why do people take glp 1 GLP-1 Agonists: Using Semaglutide, Tirzepatide, and Orforglipron for Weight Loss and Obesity The Information Survey: More Than

doi: 10.1016/j.kint.2020.06.019

Background There were two GLP-1 products that were initially approved and marketed for treating type-2 diabetes but, because they also had successful weight loss results, the manufacturers each got FDA approval to sell the products under two separate indications, one indicated for type 2 diabetes and one for weight loss, each with its own brand name and National Drug Code (NDC) identification number

In clinical trials, participants taking the highest dose of Foundayo lost an average of 1517% of their body weight over 36 to 72 weeks, compared to roughly 2% in the placebo group

Our results highlight the opportunity for pharmacogenetics and precision medicine approaches applied to GLP1 medication

The body is essentially in a constant state of tissue remodeling

The platform has been operating since 2017 and has treated millions of patients